A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

1. Alvarez, X.A.
2. Cacabelos, R.
3. Laredo, M.
4. Couceiro, V.
5. Sampedro, C.
6. Varela, M.
7. Corzo, L.
8. Fernandez-Novoa, L.
9. Vargas, M.
10. Aleixandre, M.
11. Linares, C.
12. Granizo, E.
13. Muresanu, D.
14. Moessler, H.